SandesaraPBLambertCTGordonNF, et al.Cardiac rehabilitation and risk reduction: Time to “rebrand and reinvigorate”. J Am Coll Cardiol2015; 65: 389–395.
2.
LavieCJArenaRFranklinBA. Cardiac rehabilitation and healthy life-style interventions: Rectifying program deficiencies to improve patient outcomes. J Am Coll Cardiol2016; 67: 13–15.
3.
PratesiABaldasseroniSBurgisserC, et al.Long-term functional outcomes after cardiac rehabilitation in older patients. Data from the Cardiac Rehabilitation in Advanced aGE: EXercise TRaining and Active follow-up (CR-AGE EXTRA) randomised study. Eur J Prev Cardiol2019; 26: 1470–1478.
4.
VanheesLFagardRThijsL, et al.Prognostic significance of peak exercise capacity in patients with coronary artery disease. J Am Coll Cardiol1994; 23: 358–363.
5.
CacciatoreFAmarelliCFerraraN, et al.Protective effect of physical activity on mortality in older adults with advanced chronic heart failure: A prospective observational study. Eur J Prev Cardiol2019; 26: 481–488.
6.
Marcin T, Eser P, Prescott E, et al. Predictors of pre-rehabilitation exercise capacity in elderly European cardiac patients – The EU-CaRE study. Eur J Prev Cardiol 2020; 27: 1702–1712.
7.
AdesPASavagePDBrawnerCA, et al.Aerobic capacity in patients entering cardiac rehabilitation. Circulation2006; 113: 2706–2712.
8.
Van de VeireNRde WinterOGirM, et al.Fasting blood glucose levels are related to exercise capacity in patients with coronary artery disease. Am Heart J2006; 152: 486–492.
9.
Trivi M, Thierer J, Kuschnir P, et al. Echocardiographic predictors of exercise capacity in patients with heart failure and systolic dysfunction: Role of mitral regurgitation. Rev Esp Cardiol 2011; 64: 1096–1099.
10.
KrachlerBSavonenKKomulainenP, et al.Cardiopulmonary fitness is a function of lean mass, not total body weight: The DR’s EXTRA study. Eur J Prev Cardiol2015; 22: 1171–1179.
11.
HollenbergMYangJHaightTJ, et al.Longitudinal changes in aerobic capacity: Implications for concepts of aging. J Gerontol A Biol Sci Med Sci2006; 61: 851–858.
12.
AnandIS. Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol2008; 52: 501–511.
13.
AnkerSDComin ColetJFilippatosG, et al.FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med2009; 361: 2436–2448.
14.
PonikowskiPvan VeldhuisenDJComin-ColetJ, et al.CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J2015; 36: 657–668.
15.
Van VeldhuisenDJPonikowskiPvan der MeerP, et al.EFFECT-HF Investigators. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation2017; 136: 1374–1383.
16.
LipinskiMJDeweyFEBiondi-ZoccaiG. Hemoglobin levels predict exercise performance, ST-segment depression, and outcome in patients referred for routine exercise treadmill testing. Clin Cardiol2009; 32: E22–E31.
17.
FortinMBravoGHudonC, et al.Relationship between multimorbidity and health-related quality of life of patients in primary care. Qual Life Res2006; 15: 83–91.
